CN113956245A - 克莱拉尼的晶型及其使用方法 - Google Patents

克莱拉尼的晶型及其使用方法 Download PDF

Info

Publication number
CN113956245A
CN113956245A CN202110642513.2A CN202110642513A CN113956245A CN 113956245 A CN113956245 A CN 113956245A CN 202110642513 A CN202110642513 A CN 202110642513A CN 113956245 A CN113956245 A CN 113956245A
Authority
CN
China
Prior art keywords
crystalline form
cancer
powder
peaks
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110642513.2A
Other languages
English (en)
Chinese (zh)
Inventor
维奈·简
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arog Pharmaceuticals LLC
Original Assignee
Arog Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/033618 external-priority patent/WO2022019998A1/en
Application filed by Arog Pharmaceuticals LLC filed Critical Arog Pharmaceuticals LLC
Publication of CN113956245A publication Critical patent/CN113956245A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202110642513.2A 2020-07-20 2021-06-09 克莱拉尼的晶型及其使用方法 Pending CN113956245A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063053921P 2020-07-20 2020-07-20
US63/053,921 2020-07-20
PCT/US2021/033618 WO2022019998A1 (en) 2020-07-20 2021-05-21 Crystal forms of crenolanib and methods of use thereof
USPCT/US2021/033618 2021-05-21

Publications (1)

Publication Number Publication Date
CN113956245A true CN113956245A (zh) 2022-01-21

Family

ID=79460325

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110642513.2A Pending CN113956245A (zh) 2020-07-20 2021-06-09 克莱拉尼的晶型及其使用方法

Country Status (4)

Country Link
EP (1) EP4181923A4 (https=)
JP (1) JP2023536068A (https=)
CN (1) CN113956245A (https=)
CA (1) CA3186319A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678604A (zh) * 2002-08-28 2005-10-05 辉瑞产品公司 可用作抗增殖剂的新苯并咪唑衍生物
CN1809556A (zh) * 2003-06-24 2006-07-26 辉瑞产品公司 1－[2－(苯并咪唑－1－基)喹啉－8－基]哌啶－4－基胺衍生物的制备方法
CN105294719A (zh) * 2015-11-18 2016-02-03 乳源瑶族自治县大众药品贸易有限公司 一种氨基喹唑啉类衍生物的二对甲苯磺酸盐及其晶型
CN105555272A (zh) * 2013-01-07 2016-05-04 Arog药物股份有限公司 用于治疗flt3突变型增殖性疾病的crenolanib

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101738063B1 (ko) * 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
TWI599356B (zh) * 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
EA201991078A1 (ru) * 2016-11-02 2019-11-29 Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678604A (zh) * 2002-08-28 2005-10-05 辉瑞产品公司 可用作抗增殖剂的新苯并咪唑衍生物
CN1809556A (zh) * 2003-06-24 2006-07-26 辉瑞产品公司 1－[2－(苯并咪唑－1－基)喹啉－8－基]哌啶－4－基胺衍生物的制备方法
CN105555272A (zh) * 2013-01-07 2016-05-04 Arog药物股份有限公司 用于治疗flt3突变型增殖性疾病的crenolanib
CN105294719A (zh) * 2015-11-18 2016-02-03 乳源瑶族自治县大众药品贸易有限公司 一种氨基喹唑啉类衍生物的二对甲苯磺酸盐及其晶型

Also Published As

Publication number Publication date
EP4181923A4 (en) 2024-08-07
CA3186319A1 (en) 2022-01-27
EP4181923A1 (en) 2023-05-24
JP2023536068A (ja) 2023-08-23

Similar Documents

Publication Publication Date Title
CN101578283B (zh) 噻唑烷二酮化合物的晶形及其制造方法
US11643385B2 (en) Polymorphic forms of RAD1901-2HCl
WO2016155670A1 (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2024248083A1 (ja) キノリン置換化合物の結晶
TW202308991A (zh) 三苯化合物之固體形式
WO2024165044A1 (zh) 作为蛋白激酶Mek抑制剂的多晶型物、及其制备方法和用途
US12486256B2 (en) Crystal forms of crenolanib and methods of use thereof
WO2016155578A1 (zh) 达格列净的新晶型及其制备方法
JP2024542840A (ja) Ｆｇｆｒ阻害剤の固体状形態
CN113956245A (zh) 克莱拉尼的晶型及其使用方法
AU2017267768A1 (en) Crystal of quinoline derivative
TW201008935A (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
TWI664172B (zh) 來那度胺的晶型及其製備方法和用途
TW202613103A (zh) 克萊拉尼的晶型及其使用方法
CN105753869B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
JP2024520141A (ja) 結晶形、それを含有する組成物、およびそれらの使用方法
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
TW201125861A (en) CDC7 inhibitor salts
EP4631496A1 (en) Solid dispersion, preparation method therefor, and use thereof
US20050113410A1 (en) Pharmaceutical salts of zafirlukast
WO2026095022A1 (ja) キノリン置換化合物の結晶
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
EA042455B1 (ru) Кристаллическая форма ингибитора, нацеленного на киназу cdk4/6
JPWO2002088109A1 (ja) ６−［４−（４−ピリジルアミノ）フェニル］−４，５−ジヒドロ−３（２ｈ）ピリダジノン塩酸塩三水和物の結晶
NO335256B1 (no) Krystall form (form A og C) av N-(3-cyano-4-metyl-1H-indol-7-yl)-3-cyanobenzensulfonamid og fremgangsmåte for fremstilling derav

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination